The publication of modern slavery statements (statements) on this Register does not indicate compliance with the requirements of the Modern Slavery Act 2018 (the Act). Pursuant to section 19(2) of the Act, the Attorney-General’s Department publishes all statements properly submitted to this Register, including compliant and non-compliant statements, in order to maximise transparency and ensure entities are publicly accountable for their actions to address modern slavery risks. Statements that fail to meet the requirements for approval and signature set out in sections 13(2) or 14(2) of the Act will not be registered.

Number
2023-243
Type
Joint
Title
Bristol-Myers Squibb Pty Ltd and Celgene Pty Ltd
Period
01 January 2022 to 31 December 2022
Annual revenue
500-600M
Industry sectors
Healthcare and pharmaceuticals
Countries
Australia
Key brands and business names
Bristol Myers Squibb Australia, Celgene Australia
Reporting Obligations
United Kingdom Modern Slavery Act 2015
California Transparency in Supply Chains Act 2010
Date submitted
23/03/2023
Date published
05/04/2023